Innovus Pharma Announces the Approval of Its Product ProstaGorx in Canada for Benign Prostatic Hyperplasia

Innovus Pharmaceuticals (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product for the relief of urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia.

As quoted in the press release:

“We are very delighted with the approval of ProstaGorx™ for the BPH indication in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “We currently expect ProstaGorx™ to perform very well in Canada and look forward to its launch in the very near future. ProstaGorx™, when launched, will be the fourth product launched through our own sales and marketing commercial efforts in Canada in addition to Vesele®, Apeaz® and Xyralid® and when launched will then be our eighth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation. Another of the Company’s products, AllerVarx™, a supplement for allergic rhinitis, has been approved by Health Canada, but has not yet launched.”

Click here to read the full press release.